簡(jiǎn)要描述:甲狀腺激素受體相互作用12抗體免 疫 原;KLH conjugated synthetic peptide derived from human TRIP12: 61-160/1992
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
甲狀腺激素受體相互作用12抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
甲狀腺激素受體相互作用12抗體 | TRIP12 | GOY-01K5225 |
商品屬性:
英文名稱: TRIP12
中文名:甲狀腺激素受體相互作用12抗體
別 名;KIAA0045;
MGC138849; MGC138850; Thyroid hormone receptor interactor 12; Thyroid receptor
interacting protein 12; TRIP 12.
研究領(lǐng)域;細(xì)胞生物 表觀遺傳學(xué) 泛素
抗體來源;Rabbit
克隆類型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, )
產(chǎn)品應(yīng)用;ELISA=1:5000-10000
IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;220kDa
細(xì)胞定位;細(xì)胞核
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human TRIP12: 61-160/1992
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This product
as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
TRIP12 (thyroid hormone receptor interactor 12) is
an ATP-dependent multisubunit protein that activates the proteolytic
activities of the multifunctional proteinase (20S proteasome) of the 26S
complex. TRP12 specifically interacts with the ligand binding domain of the
thyroid hormone receptor (in a thyroid hormone T3-independent manner) and
with retinoid X receptor (RXR). TRP12 was originally identified as a factor
that interacts with the thyroid hormone receptor. It was later found to also
interact with AAP-BP1, a component of the NEDD8 –activating enzyme, and function as an E3 ubiquitin
ligase for AAP-BP1. E3 ubiquitin-protein ligase involved in ubiquitin
fusion degradation (UFD) pathway and regulation of DNA repair. Part of the
ubiquitin fusion degradation (UFD) pathway, a process that mediates
ubiquitination of protein at their N-terminus, regardeless of the presence of
lysine residues in target proteins. In normal cells, mediates ubiquitination
and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor
suppressor required for p53/TP53 activation under oncogenic stress. In cancer
cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell
compartments, preventing isoform p19ARF/ARF ubiquitination and degradation.
Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also
catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation.
Ubiquitination and degradation of target proteins is regulated by interaction
with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction
between TRIP12 and target proteins. Acts as a key regulator of DNA damage
response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase
that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA
damage sites, thereby acting as a guard against excessive spreading of
ubiquitinated chromatin at damaged chromosomes. |
多克隆抗體制備:
我公司合成抗原,保證陽性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專業(yè)的建議。在制備過程中,與客戶互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶提供各種類型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶量身定制的專業(yè)服務(wù),主要面向工業(yè)客戶。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃